Advancing Vascular Health
Through Evidence-Based
Practice
From diagnostic insights to patient education materials—access the knowledge, tools, and clinical guidance that empowers better vascular care outcomes. Discover comprehensive tools and insights to advance your vascular practice—from clinical protocols and patient education to the latest research and treatment innovations.
Find More Resources In Our Community
Newest Topics
Is It Closing Time? An Update on PFO & Stroke
Newly Diagnosed Patients
August 7, 2025
A July 2025 JAMA review highlights that PFO closure has shifted from a broad intervention to a more targeted therapy, with careful patient selection—guided by two key tools—at the heart of decision-making
Is It Closing Time? An Update on PFO & Stroke
Newly Diagnosed Patients
August 7, 2025
A July 2025 JAMA review highlights that PFO closure has shifted from a broad intervention to a more targeted therapy, with careful patient selection—guided by two key tools—at the heart of decision-making
The Intersection of Metabolic Pathways and Deep Vein Thrombosis
Newly Diagnosed Patients
July 3, 2025
As we think about the educational and scientific content we share on VLN, the intersection of VTE with metabolic disorders has come up repeatedly in our discussions. How and why would metabolic disorders influence thrombosis?
The Intersection of Metabolic Pathways and Deep Vein Thrombosis
Newly Diagnosed Patients
July 3, 2025
As we think about the educational and scientific content we share on VLN, the intersection of VTE with metabolic disorders has come up repeatedly in our discussions. How and why would metabolic disorders influence thrombosis?
Popular Articles
Is It Closing Time? An Update on PFO & Stroke
Newly Diagnosed Patients
August 7, 2025
A July 2025 JAMA review highlights that PFO closure has shifted from a broad intervention to a more targeted therapy, with careful patient selection—guided by two key tools—at the heart of decision-making
Is It Closing Time? An Update on PFO & Stroke
Newly Diagnosed Patients
August 7, 2025
A July 2025 JAMA review highlights that PFO closure has shifted from a broad intervention to a more targeted therapy, with careful patient selection—guided by two key tools—at the heart of decision-making
The Intersection of Metabolic Pathways and Deep Vein Thrombosis
Newly Diagnosed Patients
July 3, 2025
As we think about the educational and scientific content we share on VLN, the intersection of VTE with metabolic disorders has come up repeatedly in our discussions. How and why would metabolic disorders influence thrombosis?
The Intersection of Metabolic Pathways and Deep Vein Thrombosis
Newly Diagnosed Patients
July 3, 2025
As we think about the educational and scientific content we share on VLN, the intersection of VTE with metabolic disorders has come up repeatedly in our discussions. How and why would metabolic disorders influence thrombosis?
Shedding Light on Bridging Therapy: A Deeper Dive into the AMBER Trial
Newly Diagnosed Patients
July 1, 2025
Alfonso J Tafur interviews McMaster University’s Dr. Alexander Godoy and Medical Student Tegvir Singh Grewal at ISTH 2025
Shedding Light on Bridging Therapy: A Deeper Dive into the AMBER Trial
Newly Diagnosed Patients
July 1, 2025
Alfonso J Tafur interviews McMaster University’s Dr. Alexander Godoy and Medical Student Tegvir Singh Grewal at ISTH 2025
Optimising communication to patients with venous thromboembolism: development of a provider toolkit
Newly Diagnosed Patients
June 5, 2025
This In Focus feature in Lancet Haematology highlights the creation of a global clinician toolkit designed to enhance clear, compassionate communication throughout the VTE diagnostic journey and beyond.
Optimising communication to patients with venous thromboembolism: development of a provider toolkit
Newly Diagnosed Patients
June 5, 2025
This In Focus feature in Lancet Haematology highlights the creation of a global clinician toolkit designed to enhance clear, compassionate communication throughout the VTE diagnostic journey and beyond.
Unmet Needs in Atrial Fibrillation (AF) and the Promise of Factor XI as a New Therapeutic Target
Newly Diagnosed Patients
March 26, 2025
This presentation explores the persistent challenges in managing atrial fibrillation (AF) — particularly the limitations of current oral anticoagulants. While therapies like warfarin and DOACs have been transformative, concerns about bleeding, dosing complexity, and adherence continue to impact real-world effectiveness.
Unmet Needs in Atrial Fibrillation (AF) and the Promise of Factor XI as a New Therapeutic Target
Newly Diagnosed Patients
March 26, 2025
This presentation explores the persistent challenges in managing atrial fibrillation (AF) — particularly the limitations of current oral anticoagulants. While therapies like warfarin and DOACs have been transformative, concerns about bleeding, dosing complexity, and adherence continue to impact real-world effectiveness.
Keep a Pulse on Progress
Explore our community and collaborate to build and utilize top-tier, trustworthy, and balanced medical education
Keep a Pulse on Progress
Explore our community and collaborate to build and utilize top-tier, trustworthy, and balanced medical education
Keep a Pulse on Progress
Explore our community and collaborate to build and utilize top-tier, trustworthy, and balanced medical education